What came first, the advisor or the high-risk, high-priced product?

Blue Owl and FS KKR Losses Put BDC Profitability Under Scrutiny

Blue Owl Technology Finance and FS KKR Capital both reported first-quarter losses after valuation declines outweighed positive investment in

Leveraged ETFs Are Booming, But Are Advisors Buying?

Clients don’t tend to want them, but those who do should be wary of the risks, advisors said. The post Leveraged ETFs Are Booming, But Are A

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

This could be a key move for future growth.

Bernstein says the future of tech is quantum. These two stocks have the most upside

While it is too early to identify the ultimate winners in quantum computing, two stocks already offer more attractive risk-reward ratios, Wa

The Banking Strategy That Keeps Growing More Valuable in Uncertain Times

Biotech ETFs: How Do FBT and IBB Match Up on Cost, Structure, and Performance?

First Trust's 30-stock strategy delivered 53.2% returns over one year, but comes with higher concentration risk and a steeper 11-basis-point